Clinical trialNCT03384914Active, not recruitingPhase 2Interventional

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment119Breast Cancer FemaleBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer, MaleHER2 Positive Breast Carcinoma+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Hyo S. Han, M.D.
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Emory - Winship Cancer Institute
Atlanta, Georgia, United States
Indiana University - Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Ohio State University - Arthur G James Cancer Hospital & Richard J Solove Research Institute
Columbus, Ohio, United States
University of Washington, Fred Hutchinson Cancer Research Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DC1 VaccineWOKVAC Vaccine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Feb 2018
Primary completion: 22 Dec 2025
Completion: 31 Dec 2027
Last update posted: 6 Mar 2026
Registered enrollment: 119
Registry id: NCT03384914

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.